Untapped market Cyrano Therapeutics targets persistent post-viral smell and taste disorders with CYR-064, addressing a large unmet need in the US and Europe. This creates a potential sales opportunity for niche pharmaceutical distributors, ENT clinics, and rehabilitation centers focusing on anosmia/hyposmia and quality of life improvements.

Phase 2 momentum Current Phase 2 randomized trial across 14 US sites with data readout expected in Q1 2025 signals near-term clinical data utility. Opportunities exist to engage potential clinical trial collaborators, contract research organizations, and site networks for accelerated access programs or post-trial commercialization discussions.

Strategic partnerships With a small, focused team and credible funding history, Cyrano is positioned to seek co-development, licensing, or distribution partnerships with larger pharma companies or specialty biotech firms, especially those with otolaryngology, neurology, or regenerative medicine portfolios.

Early-stage traction Historical fundraising and board-level involvement indicate investor confidence. Potential sales angles include pursuing early access arrangements, payer demonstrations of value in improving safety and quality of life, and building case studies to support reimbursement negotiations.

Global growth channel Given the widespread prevalence of smell and taste disorders and the absence of marketed therapies, there is a clear opportunity to develop international distribution plans, engage global regulatory consultants, and target specialty clinics and hospital networks outside the US to capture early-market adoption.